May 28, 2020
FDA Alerts Patients and Health Care Professionals to Nitrosamine Impurity Findings in Certain Metformin Extended-Release Products
May 18, 2020
Roopal Luhana Appointed to Plaintiffs' Steering Committee for Zantac MDL
May 12, 2020
Pope McGlamry P.C. Announces Plaintiffs' Leadership Role in the Zantac/Ranitidine Products Liability Litigation
May 01, 2020
Advisory - Axid (nizatidine) drug recalled due to presence of NDMA
Apr 02, 2020
Carlson Law Firm Assisting Clients Suffering from Zantac-Related Cancer
Apr 01, 2020
Media Briefing: FDA Requests Removal of All Ranitidine Products (Zantac) from the Market
Apr 01, 2020
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market
Mar 11, 2020
Information Update - Certain Metformin diabetes drugs recalled due to the presence or possible presence of NDMA
Feb 05, 2020
Information Update - Apotex Inc. recalls certain lots of the diabetes medication APO-Metformin ER (extended release) 500 mg tablets
Dec 05, 2019
Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S.
Nov 01, 2019
Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research on new testing results, including low levels of impurities in ranitidine drugs
Oct 30, 2019
Information Update - Ranbaxy Pharmaceuticals Canada Inc. recalls prescription ranitidine products as a precaution; request to stop distribution remains in place while Health Canada continues to assess NDMA
Oct 23, 2019
Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product
Oct 18, 2019
Sanofi to conduct precautionary voluntary recall of Zantac OTC in Canada and the U.S.
Sep 25, 2019
Information Update - Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; additional products being recalled
Sep 24, 2019
FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity
Sep 23, 2019
Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product
Sep 13, 2019
Information Update - Health Canada assessing NDMA in ranitidine
Sep 13, 2019
Statement from FDA's Center for Drug Evaluation and Research Director Janet Woodcock, M.D., alerting patients and health care professionals of NDMA found in samples of ranitidine